Survey of Ophthalmology
Volume 55, Issue 4 , Pages 378-385 , July 2010

Drug-induced Optic Neuropathy—TB or Not TB

  • Monika Pradhan, MS, MRCOphth

      Affiliations

    • Department of Ophthalmology, National Eye Centre, University of Auckland, New Zealand
    • Department of Ophthalmology, Greenlane Clinical Centre, Auckland District Health Board, New Zealand
    • ,
  • Dianne Sharp, FRANZCO

      Affiliations

    • Department of Ophthalmology, National Eye Centre, University of Auckland, New Zealand
    • ,
  • Stephen Best, FRANZCO

      Affiliations

    • Department of Ophthalmology, National Eye Centre, University of Auckland, New Zealand
    • ,
  • Andrea Vincent, FRANZCO

      Affiliations

    • Department of Ophthalmology, National Eye Centre, University of Auckland, New Zealand
    • Department of Ophthalmology, Greenlane Clinical Centre, Auckland District Health Board, New Zealand
    • Corresponding Author InformationReprint address: Dr Andrea Vincent, Department of Ophthalmology, University of Auckland, Private Bag 92019, Auckland, New Zealand.
    • ,
  • Michael Vaphiades, DO

      Affiliations

    • Department of Ophthalmology, University of Alabama, Birmingham, Alabama, USA

References 

  1. Optic neuritis study group . The clinical profile of optic neuritis: experience of the Optic neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673–1678
  2. Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211–215
  3. Beck RW. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673–1678
  4. Berninger TA, Jaeger W, Krastel H. Electrophysiology and colour perimetry in dominant infantile optic atrophy. Br J Ophthalmol. 1991;75:49–52
  5. Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J. 2006;12:56–60
  6. Chowdhury B, Nagpaul AK, Chowdhury D. Leber's hereditary optic neuropathy masquerading as ethambutol-induced optic neuropathy in a young male. Indian J Ophthalmol. 2006;54:218–219
  7. Chuenkongkaew W, Samsen P, Thanasombatsakul N. Ethambutol and optic neuropathy. J Med Assoc Thai. 2003;86:622–625
  8. Chung H, Yoon YH, Hwang JJ, et al. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol. 2009;235:163–170
  9. Delettre C, Lenaers G, Griffoin JM, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26:207–210
  10. Dinkin MJ, Cestari DM, Stein MC, et al. NMO antibody-positive recurrent optic neuritis without clear evidence of transverse myelitis. Arch Ophthalmol. 2008;126:566–570
  11. Gelwan MJ, Kellen RI, Burde RM, et al. Sarcoidosis of the anterior visual pathway: successes and failures. J Neurol Neurosurg Psychiatry. 1988;51:1473–1480
  12. Heng JE, Vorwerk CK, Lessell E, et al. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest Ophthalmol Vis Sci. 1999;40:190–196
  13. Ikeda A, Ikeda T, Ikeda N, et al. Leber's hereditary optic neuropathy precipitated by ethambutol. Jpn J Ophthalmol. 2006;50:280–283
  14. Kjer P, Jensen OA, Klinken L. Histopathology of eye, optic nerve and brain in a case of dominant optic atrophy. Acta Ophthalmol (Copenh). 1983;61:300–312
  15. Kumar A, Sandramouli S, Verma L, et al. Ocular ethambutol toxicity: is it reversible?. J Clin Neuroophthalmol. 1993;13:15–17
  16. Kupersmith MJ, Alban T, Zeiffer B, et al. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain. 2002;125:812–822
  17. Lee EJ, Kim SJ, Choung HK, et al. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol. 2008;28:269–277
  18. Lenaers G, Reynier P, Elachouri G, et al. OPA1 functions in mitochondria and dysfunctions in optic nerve. Int J Biochem Cell Biol. 2009;41:1866–1874
  19. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112
  20. Lepore FE. The origin of pain in optic neuritis: determinants of pain in 101 eyes with optic neuritis. Arch Neurol. 1991;48:748–749
  21. Mackey DA, Fingert JH, Luzhansky JZ, et al. Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus. Eye. 2003;17:312–317
  22. Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc. 2003;78:1409–1411
  23. Olichon A, Baricault L, Gas N, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278:7743–7746
  24. Olichon A, Emorine LJ, Descoins E, et al. The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space. FEBS Lett. 2002;523:171–176
  25. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390–396
  26. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991;109:1668–1672
  27. Sarkies NJ. Optic nerve sheath meningioma: diagnostic features and therapeutic alternatives. Eye. 1987;1:597–602
  28. Sibony PA, Krauss HR, Kennerdell JS, et al. Optic nerve sheath meningiomas. Clinical manifestations. Ophthalmology. 1984;91:1313–1326
  29. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42:909–917
  30. Talbert Estlin KA, Sadun AA. Risk factors for ethambutol optic toxicity. Int Ophthalmol. 2009;Feb 11 [Epub ahead of print]
  31. Vaphiades MS, Newman NJ. Optic nerve enhancement on the orbital magnetic resonance imaging and Leber's hereditary optic neuropathy. J Neuroophthalmol. 1989;19:238–239
  32. Votruba M. Molecular genetic basis of primary inherited optic neuropathies. Eye. 2004;18:1126–1132
  33. Votruba M, Aijaz S, Moore AT. A review of primary hereditary optic neuropathies. J Inherit Metab Dis. 2003;26:209–227
  34. Votruba M, Moore AT, Bhattacharya SS. Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. J Med Genet. 1998;35:793–800
  35. White KE, Davies VJ, Hogan VE, et al. OPA1 deficiency associated with increased autophagy in retinal ganglion cells in a murine model of dominant optic atrophy. Invest Ophthalmol Vis Sci. 2009;50:2567–2571
  36. Wingerchuk DM. Neuromyelitis optica. Adv Neurol. 2006;98:319–333
  37. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53:1107–1114
  38. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(09)00269-0

doi: 10.1016/j.survophthal.2009.10.005

Survey of Ophthalmology
Volume 55, Issue 4 , Pages 378-385 , July 2010

Article Tools

* Image Usage & Resolution